Fluifort, 90 mg/ml syrup 120 ml

Pharmacodynamics

Carbocysteine lysine salt restores viscosity and elasticity of mucous secretion of the upper and lower airways. The effect is dose-dependent.

Mucolytic and expectorant effect of carbocysteine lysine salt is due to the activation of sialic transferase (enzyme of the mucous membrane of the bronchi). Normalizes the quantitative ratio of acidic and neutral mucins of the bronchial secretion: decreases the number of neutral glycopeptides and increases the number of hydroxyalcoholicopeptides. Reduces the viscosity of bronchial secretion and nasal sinus discharge, facilitates discharge of sputum and mucus, reduces coughing. Promotes mucous membrane regeneration, normalizes its structure, reduces the number of bocalytic cells, especially in the terminal bronchi, and, as a consequence, reduces mucus production. It restores secretion of immunologically active IgA (specific protection), improves mucociliary clearance and antibiotic transport.

In addition, carbocysteine lysine salt stimulates secretion of chlorine ions in airway epithelium. This phenomenon is associated with the transport of water and thus with the liquefaction of the mucous secretion. Carbocysteine lysine salt increases the concentration of lactoferrin, lysozyme and α1-antitrypsin, indicating the functional recovery of mucosal bronchial gland cells and their protein synthesis mechanism.

Carbocysteine lysine salt is a neutral compound (pH 6.8), is well soluble in water and therefore does not irritate the mucous membrane of the stomach, which allows prescribing a daily dose at one time.

Pharmacokinetics

Quickly and almost completely absorbed after oral administration. Bioavailability of carbocysteine lysine salt is low (less than 10% of the dose taken) and does not depend on the dosage form.

Maximum Cmax concentration in blood and mucosa is reached after 1.5 – 2 hours. The plasma elimination half-life is 2-3 hours. Like all derivatives with blocked thiolytic group, carbocysteine lysine salt has the highest affinity to bronchopulmonary tissue. The drug reaches an average concentration in mucosa of 3.5 µg/ml with half-life of about 1.8 hours (2 g daily dose).

Complete excretion occurs after 3 days. Excretion is primarily by the kidneys. A part of the drug is excreted unchanged by the kidneys, the rest is excreted as metabolites.

Indications

Acute and chronic bronchopulmonary diseases accompanied with formation of viscous and hardly discharged sputum (tracheitis, bronchitis, tracheobronchitis, bronchial asthma, bronchiectatic disease) and mucus (inflammatory diseases of the middle ear and accessory sinuses – rhinitis, adenoiditis, otitis media, sinusitis).

Patient preparation for bronchoscopy or bronchography.

Active ingredient

Composition

100 ml of syrup contains:

the active ingredient:

carbocysteine lysine salt monohydrate 9 g,

excipients:

sucrose – 40 g;

cherry essence natural – 0.25 g;

methyl-p-hydroxybenzoate – 0.15 g;

caramel – 0.03 g;

purified water – up to 100 ml

How to take, the dosage

Interaction

Special Instructions

Synopsis

Contraindications

Gastric and duodenal ulcer (acute phase);

Pregnancy;

Children under 2 years of age;

Sugar/isomaltase deficiency;

Fructose intolerance;

Glucose-galactose malabsorption (because the drug contains sucrose.Because the drug contains sucrose).

Side effects

Experience with Fluifort indicates that adverse reactions are very rare (incidence < 1/10,000):

All of these disorders are transient and disappear after discontinuation of the drug or after reducing the dosage.

If any side effect occurs, discontinue the drug and see a physician immediately.

Overdose

Similarities